67 related articles for article (PubMed ID: 12866968)
41. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing.
Eisbruch A; Marsh LH; Dawson LA; Bradford CR; Teknos TN; Chepeha DB; Worden FP; Urba S; Lin A; Schipper MJ; Wolf GT
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):28-42. PubMed ID: 15093896
[TBL] [Abstract][Full Text] [Related]
42. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma.
Chua DT; Wei WI; Sham JS; Cheng AC; Au G
Head Neck; 2003 Jul; 25(7):585-94. PubMed ID: 12808662
[TBL] [Abstract][Full Text] [Related]
43. [Dosimetric analysis of radiotherapy with middle shielding blocks of different widths at the lower cervical supraclavicular field for stage N2-3 nasopharyngeal carcinoma].
Li FM; Luo W; He ZC; Zhang L; Sun Y; Qin WJ; Lu LX; Han F; Liu XQ; Liu MZ
Ai Zheng; 2007 Oct; 26(10):1127-32. PubMed ID: 17927886
[TBL] [Abstract][Full Text] [Related]
44. [Important prognostic factors in patients with skull base erosion from nasopharyngeal carcinoma after radiotherapy].
Hu Y; Lu T; Mai W; Han F; Huang Y; Liu H; Zhang E
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Dec; 36(6):463-7. PubMed ID: 12761966
[TBL] [Abstract][Full Text] [Related]
45. Cancer of the nasopharynx in British Columbia.
Flores AD; Dickson RI; Riding K; Coy P
Am J Clin Oncol; 1986 Aug; 9(4):281-91. PubMed ID: 3751965
[TBL] [Abstract][Full Text] [Related]
46. [Changes of hypoxia in primary lesion of nasopharyngeal carcinoma during the treatment course and the clinical value thereof].
Zheng YJ; Zhao C; Fan W; Liu H; Cui NJ; Chen FJ
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2698-702. PubMed ID: 18167248
[TBL] [Abstract][Full Text] [Related]
47. Hypothalamic pituitary dysfunction after nasopharyngeal carcinoma irradiation.
Bouzid N; Chamsi A; Barka I; Sghaier S; Tbessi S; Elleuch K; Tebra S
Clin Neurol Neurosurg; 2024 Jan; 236():108100. PubMed ID: 38218060
[TBL] [Abstract][Full Text] [Related]
48. The effect of radiotherapy on mucociliary clearance in patients with laryngeal and nasopharyngeal cancer.
Kılıç C; Tunçel Ü; Cömert E; Kaya BV
Eur Arch Otorhinolaryngol; 2015 Jun; 272(6):1517-20. PubMed ID: 24838358
[TBL] [Abstract][Full Text] [Related]
49. Hydrogen-oxygen therapy can alleviate radiotherapy-induced hearing loss in patients with nasopharyngeal cancer.
Chen J; Kong X; Mu F; Lu T; Du D; Xu K
Ann Palliat Med; 2019 Nov; 8(5):746-751. PubMed ID: 31865734
[TBL] [Abstract][Full Text] [Related]
50. Symptom distress, catastrophic thinking, and hope in nasopharyngeal carcinoma patients.
Lai YH; Chang JT; Keefe FJ; Chiou CF; Chen SC; Feng SC; Dou SJ; Liao MN
Cancer Nurs; 2003 Dec; 26(6):485-93. PubMed ID: 15022980
[TBL] [Abstract][Full Text] [Related]
51. Patient-Derived Nasopharyngeal Cancer Organoids for Disease Modeling and Radiation Dose Optimization.
Lucky SS; Law M; Lui MH; Mong J; Shi J; Yu S; Yoon DK; Djeng SK; Wang J; Lim CM; Tan MH
Front Oncol; 2021; 11():622244. PubMed ID: 33732646
[TBL] [Abstract][Full Text] [Related]
52. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
Lu TX; Mai WY; Teh BS; Zhao C; Han F; Huang Y; Deng XW; Lu LX; Huang SM; Zeng ZF; Lin CG; Lu HH; Chiu JK; Carpenter LS; Grant WH; Woo SY; Cui NJ; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):682-7. PubMed ID: 14967420
[TBL] [Abstract][Full Text] [Related]
53. [Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma].
Zhao C; Han F; Lu LX; Huang SM; Lin CG; Deng XW; Lu TX; Cui NJ
Ai Zheng; 2004 Nov; 23(11 Suppl):1532-7. PubMed ID: 15566674
[TBL] [Abstract][Full Text] [Related]
54. Sequential external beam radiotherapy and high-dose-rate intracavitary brachytherapy in T1 and T2 nasopharyngeal carcinoma: an evaluation of long-term outcome.
Thiagarajan A; Lin K; Tiong CE; Tan LK; Loh TK; Goh BC; Lu JJ
Laryngoscope; 2006 Jun; 116(6):938-43. PubMed ID: 16735885
[TBL] [Abstract][Full Text] [Related]
55. Impairment mechanism of nasal mucosa after radiotherapy for nasopharyngeal carcinoma.
Fang C; Zhong Y; Chen T; Li D; Li C; Qi X; Zhu J; Wang R; Zhu J; Wang S; Ruan Y; Zhou M
Front Oncol; 2022; 12():1010131. PubMed ID: 36591522
[TBL] [Abstract][Full Text] [Related]
56. [Clinical observation of hypoxic radiotherapy for nasopharyngeal carcinoma].
Xia HS; Han SY; Li P; Liu ZC; Tang PY
Ai Zheng; 2003 Jul; 22(7):745-8. PubMed ID: 12866968
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
